

At page 47, lines 12-16, please replace the Table with the following replacement Table:

05

Assay	Name	Sequence (5'-3')
CYP2A6*2 (v ₁) and CYP2A6*3 (v ₂)	F4	CCTCCCTTGCTGGCTGTGTCCCAAGCTTAGGC (SEQ ID NO: 8)
	R4	CGCCCCTTCCTTTCCGCCATCCTGCCCCCAG (SEQ ID NO: 9)
	E3F	GCGTGGTATTCAGCAACGGG (SEQ ID NO: 10)
	E3R	TCGTGGGTGTTTTCCTTC (SEQ ID NO: 11)

AMENDMENTS TO THE DRAWINGS

Applicants submit herewith proposed amendments to Figures 2A and 2B under 37 C.F.R. § 1.121. The proposed amendments to the figures are presented in red ink on a separate sheet for each respective figure, for approval by the Examiner. Applicants respectfully request consideration of the proposed amendments to the Figures and notification of acceptance of the Figure amendments by the Examiner.

IN THE CLAIMS:

Please amend claims 2, 11-13, 16, 21-23, 30, and 38 and add claims 39-44. Please cancel claims 1, 3, 4, 7- 9, and 34-36. Claims 2, 11-13, 16, 21-23, 30, and 38-44 are provided in a clean format in accordance with 37 C.F.R. § 1.121. A redline version of the claims are provided in Appendix A.

06 Subst
2. (Amended) The method of claim 11 or 17, wherein CYP2A6 is selectively inhibited using one or more of the following (i) substances which inhibit CYP2A6 activity; or (ii) substances which inhibit transcription and/or translation of the gene encoding CYP2A6.

07 Subst
11. (Amended) A method for treating a condition requiring regulation of nicotine metabolism to cotinine in an individual comprising administering to said individual an effective amount of a substance which selectively inhibits CYP2A6.